

# Prevalence and Clinical Characteristics of Hypothyroidism in a Population Undergoing Maintenance Hemodialysis

KLARA PAUDEL

## ABSTRACT

**Background:** The prevalence of hypothyroidism in persons with chronic kidney disease is documented to be higher, compared to the normal population. However, no data is available about the prevalence rate of hypothyroidism among hemodialysis patients in Nepal.

**Methods:** A cross-sectional analysis was done on consecutive patients enrolled for maintenance hemodialysis in the Hemodialysis Unit of Gandaki Medical College Teaching Hospital, Pokhara, Nepal, during the period of one year (1<sup>st</sup> January 2011 to 31<sup>st</sup> December 2011). Total 64 subjects with end stage renal disease were recruited for the study. Thyroid function tests were performed at the time of starting regular hemodialysis. Classical symptoms and signs of hypothyroidism were assessed in all patients.

**Results:** Among the study subjects 17 (26.6%) had serum thyroid stimulating hormone levels above the laboratory reference range (>6.16  $\mu$ U/ml). Among them 12 (18.7%) patients had clinically significant symptoms or signs requiring thyroxin replacement. Cold intolerance, constipation, tingling sensation, dry skin, periorbital edema, pericardial effusion, pleural effusion and ascites were found at significantly higher rate in the hypothyroid patient group ( $p < 0.05$ ).

**Conclusion:** The diagnosis of hypothyroidism can be easily missed in the end-stage kidney disease population, because the symptoms of chronic kidney disease and hypothyroidism overlap. In our study we have found high prevalence of hypothyroidism. Clinicians should pay attention on this factor and screen routinely for thyroid disorders in the chronic kidney disease population.

## INTRODUCTION

End stage renal disease alters the hypothalamic-pituitary-thyroid hormone axis [1] in addition to the peripheral thyroid hormone metabolism [2].

Increased prevalence of goiter and thyroid gland volume have been reported in patients with end-stage renal disease (ESRD) [3,4] and there are also studies reporting increased prevalence of primary hypothyroidism among ESRD patients compared with the general population [5]. Thyroid hormone abnormalities have been reported among euthyroid patients with ESRD, including reduced total and free triiodothyronine (T3) and thyroxine (T4) levels [6]. The background for these abnormalities is unclear, however it has been postulated to be due to adaptive response to chronic nonthyroidal illness, uremia and protein malnutrition [7].

In ESRD patients, the symptoms of chronic kidney disease (CKD) and hypothyroidism overlap in many aspects, making it difficult to recognize primary hypothyroidism, unless one has a high level of suspicion.

In our research, we were exploring the burden of primary hypothyroidism in an ESRD population undergoing regular hemodialysis in Nepal. We were also trying to find answers as to, which are the typical symptoms or signs, more characteristic for hypothyroidism, which should prompt the physicians to do thyroid testing in this special population.

## METHODS

### Subjects

The study was performed on hemodialysis patients suffering from chronic kidney disease, enrolled for maintenance treatment at the Hemodialysis Unit in Gandaki Medical College Teaching Hospital

**Keywords:** Chronic kidney disease, Thyroid disorder, Nepal

(GMCTH, also known as Charak Hospital and Research Center), Pokhara, Nepal, during the period of 1<sup>st</sup> January 2011 to 31<sup>st</sup> December 2011.

A total of 64 subjects were enrolled. We invited all existing and new patients during the study period. Inclusion criteria were: age above 18 years, CKD stage 5 on hemodialysis, willing to consent for the study. Exclusion criteria: under treatment for thyroid disorders, unable to answer the questionnaire.

The study population's mean age was  $47.2 \pm 15.6$  years. Female to male ratio is 1:3.3 (number of female subjects was 15 and male 49).

### Ethical Considerations

Informed consent was taken from all the patients. The study protocol was approved by the institutional review board.

### Laboratory Measurement

Blood for laboratory analysis was collected on the day of hemodialysis. In patients with AV fistula, the blood was drawn through the fistula needle immediately after insertion, before starting the hemodialysis procedure. In patients with double lumen catheter, the blood was drawn from the catheter, in similar way.

Thyroid function tests (thyroid stimulating hormone (TSH), free T4 and free T3 serum levels) were performed using ELISA method (Ranbaxy Diagnostics, India) in the central laboratory of GMCTH. The normal reference range for TSH, FT4 and FT3 was 0.39-6.16  $\mu$ U/ml, 0.8-2.0 ng/dl, 1.4-4.2 pg/ml respectively.

### Questionnaire

Subjects were interrogated by a medical doctor and the presence or absence of nine symptoms of hypothyroidism were recorded. Periorbital edema was assessed by the same person. The presence

of pericardial or pleural effusion and ascites were assessed by ultrasound and echocardiography performed by experienced ultrasonographers.

## STATISTICAL ANALYSIS

Statistical calculation was done using SPSS 14.0 software. All continuous variables are expressed as mean  $\pm$  SD and proportions are expressed as a number (%). For comparing proportions we have used Chi-square test or Fisher's exact test as appropriate.

## RESULTS

### TSH Levels among the Subjects

The mean TSH level in the whole group was  $5.16 \pm 5.74$   $\mu$ U/ml. Based on the TSH levels, the subjects were classified into three groups: low TSH (TSH  $\leq$  0.38  $\mu$ U/ml, Group 1), normal TSH (TSH 0.39-6.16  $\mu$ U/ml, Group 2) and high TSH (TSH  $\geq$  6.17  $\mu$ U/ml, Group 3) [Table/Fig-1]. Data analysis has showed, that 3.13% patients had lower range TSH levels, 70.3% had normal TSH and 26.6% of patients had high TSH levels. The mean thyroid function values are displayed in [Table/Fig-1]. Among patients with high ( $\geq$  6.17  $\mu$ U/ml) TSH levels, 3 had normal range fT4 and fT3 levels, considered as subclinical hypothyroidism, the rest of the subjects had low fT4 levels (fT4  $<$  0.8 ng/dl), considered as hypothyroid subjects. Among the 17 patients in the hypothyroid group, 12 (18.7%) patients had clinically significant symptoms or signs requiring thyroxin replacement.

The female to male ratio did not change significantly in the different groups, compared to the ratio found in the study population.

	Group 1 (TSH $\leq$ 0.38 $\mu$ U/ml)	Group 2 (TSH 0.39-6.16 $\mu$ U/ml)	Group 3 (TSH $\geq$ 6.17 $\mu$ U/ml)
n	2 (3.13%)	45 (70.3%)	17 (26.6%)
Female/Male ratio	1/1	12/33	3/14
Mean age (years)	$45 \pm 14.1$	$48.7 \pm 17.9$	$42.1 \pm 13.5$
Mean TSH level ( $\mu$ U/ml)	$0.16 \pm 0.19$	$2.92 \pm 1.59$	$11.32 \pm 7.26$
Mean fT4 level (ng/dl)	$1.15 \pm 0.07$	$1.18 \pm 0.39$	$0.73 \pm 0.30$
Mean fT3 level (pg/ml)	$2.5 \pm 1.13$	$2.60 \pm 0.67$	$1.54 \pm 0.74$

[Table/Fig-1]: Clinical characteristics of the patient groups based on TSH level

### Clinical Symptoms and Signs Associated with Hypothyroidism

The classical symptoms and signs of hypothyroidism were accessed and analysed in the euthyroid and hypothyroid groups, as seen in [Table/Fig-2]. All symptoms were found present in both groups, but there are differences in the prevalence. Using Chi-square test and Fisher's exact test, as appropriate, we have compared the symptom prevalence between the two groups. Among the symptoms, cold intolerance, constipation, dry skin, tingling sensation and muscle pain or weakness were significantly more prevalent in the hypothyroid group. Among the signs, periorbital odema, pericardial and pleural effusions and ascites were significantly more prevalent in the hypothyroid group.

More than half of the patients with any kind of effusions eg. pleural, pericardial or ascites, had elevated TSH.

## DISCUSSION

In our study we have found high prevalence of primary hypothyroidism in a dialysis patient population. There are no population-based data about the prevalence of thyroid disorders in Nepal. According to reports from developed countries, the prevalence of primary hypothyroidism (TSH  $>$  6  $\mu$ U/ml) is 7.5% in women and 2.8% in men [8], and it is reported to be 5% in multiple populations [9]. One recent Indian population-based study done in Cochin on 971

	Euthyroid group (TSH 0.39- 6.16 $\mu$ U/ml)	Hypothyroid group (TSH $\geq$ 6.17 $\mu$ U/ml)	P-value	OR (95% CI)
<b>Symptoms</b>				
Fatigue	16/45 (35.6%)	10/17 (58.8%)	NS	2.59 (0.82-8.12)
Cold intolerance	2/45 (4.4%)	10/17 (58.8%)	$<$ 0.0001	30.71 (5.52-170.76)
Constipation	13/45 (28.9%)	10/17 (58.8%)	$<$ 0.05	3.52 (1.10-11.23)
Dry skin	16/45 (35.6%)	12/17 (70.6%)	$<$ 0.01	4.35 (1.30-14.57)
Tingling sensation	4/45 (8.9%)	9/17 (52.9%)	$<$ 0.001	11.53 (2.84-46.78)
Poor concentration/ memory	8/45 (17.8%)	5/17 (29.4%)	NS	1.93 (0.53-7.02)
Muscle pain/ muscle weakness	10/45 (22.2%)	8/17 (47.1%)	$<$ 0.05	3.11 (0.95-10.16)
Anxiety/ Depression	9/45 (20.0%)	5/17 (29.4%)	NS	1.66 (0.47-5.9)
Hair loss	3/45 (6.7%)	1/17 (5.9%)	NS	0.875 (0.08-9.04)
<b>Signs</b>				
Periorbital odema	7/45 (15.6%)	13/17 (76.5%)	$<$ 0.0001	17.64 (4.44-70.16)
Pericardial effusion	7/45 (15.6%)	9/17 (52.9%)	$<$ 0.01	6.11 (1.75-21.27)
Pleural effusion	3/45 (6.7%)	9/17 (52.9%)	$<$ 0.001	15.75 (3.48-71.27)
Ascites	6/45 (13.3%)	7/17 (41.2%)	$<$ 0.05	4.55 (1.25-16.57)

[Table/Fig-2]: Symptom prevalence in the euthyroid and hypothyroid groups  
Note: NS: not significant

adult subjects, the prevalence of hypothyroidism was 3.9%, and prevalence of subclinical hypothyroidism was 9.4% [10].

The analysis of the third national survey in the United States revealed, that among patients with chronic kidney disease, the prevalence of hypothyroidism increases with lower levels of glomerulus filtration rate (GFR), in subjects with GFR  $<$ 30 ml/min/1.73m<sup>2</sup> the prevalence was 23.1% [11]. In another cross-sectional analysis in Italy, the prevalence of subclinical hypothyroidism was found to be 17.9% in persons with GFR  $<$ 60 ml/min/1.73m<sup>2</sup> [12].

In our study among the 64 hemodialysis patients, 17 (26.6%) had elevated TSH, and only 3 of them was considered as subclinical hypothyroidism based on the normal fT4 levels.

In our dialysis patient population the female:male ratio was 1:3.27, and there is no significant difference in the ratio among the euthyroid and hypothyroid groups. In most studies the hypothyroidism is reported to be more frequent in women (in general population, not in CKD population).

It is common to find the classical symptoms and signs both in the euthyroid and hypothyroid individuals. However, they will be found more frequently among the hypothyroid people. In the Colorado Thyroid Survey constipation and cold intolerance were the symptoms associated significantly with the disease state [13].

There are multiple factors leading to thyroid abnormalities in patients with CKD. Due to reduced deiodinase activity, tissue and circulating levels of the active form of T3 are low in kidney failure [14]. Because of reduced renal excretion, inorganic iodide generated by residual deiodinase activity accumulates in stage 4 and 5 CKD, which in turn dampens thyroid hormone synthesis. On the other hand, accumulation of toxic uremic solutes alters the central (hypothalamic) control of the pituitary gland, and the TSH response to thyrotropin-releasing hormone is subnormal in these patients [15]. In contrast,

the thyroid-pituitary feedback loop seems to remain intact, because steady-state plasma TSH remains substantially normal and TSH undergoes the expected rise after thyroidectomy in these patients [16]. Central effects apart, toxic uremic solutes inhibit protein binding of thyroxine [17]. Furthermore, studies in the last decade showed that systemic inflammation [6,18] and metabolic acidosis [19] might alter thyroid function in CKD patients.

The kidney contributes to the iodine clearance primarily through glomerular filtration. Serum iodine concentrations are high in CKD but are not correlated with the degree of kidney failure [20]. Elevation of serum iodine levels result in prolongation of the Wolff-Chaikoff effect [21]. Iodine excess has been linked to increased prevalence of goiter and hypothyroidism reported in CKD [14, 22]. A high exposure to iodine facilitates the development of hypothyroidism in CKD patients [23]. Some authors have reported that a restriction of dietary iodine in uraemic patients on HD can correct the hypothyroidism avoiding the need for hormone replacement with levothyroxine [24].

Undiagnosed and untreated hypothyroidism is posing danger on CKD patients in many ways. First, ESRD patients have a well-recognized increased risk of cardiovascular disease that begins early in the course of CKD and results in 10-fold or higher cardiovascular mortality rates after the start of renal replacement therapy [25]. Hypothyroidism itself is also a risk factor for cardiovascular disease [26], thus adding to the existing risks. However hypothyroidism is a modifiable risk factor, hence should be recognized and treated on time. Second, hypothyroidism impairs myocardial function [27]. In CKD patients cardiac function can be already challenged by fluid overload, overt hypertension, anemia, etc., leading to cardiac failure. Hypothyroidism can worsen the situation. Third, certain neurobehavioral and neuromuscular dysfunctions are also associated with hypothyroidism, e.g. depression, memory loss, cognitive impairment and peripheral nerve dysfunction [28-30]. The prevalence of depression in dialysis patients is high [31], and hypothyroidism can contribute to its development. Fourth, hypothyroidism is associated with anemia, approximately 20-60% of patients with hypothyroidism are also diagnosed with anemia [32]. It can have various etiologies, and can manifest as normocytic, microcytic or macrocytic anemia [33]. In patients on maintenance hemodialysis, erythropoietin resistance is a common problem, and hypothyroidism should be also ruled out together with the other well-known causes. Last but not least, symptoms of hypothyroidism can further decrease the quality of life of CKD patients, which is already much affected due to the kidney disease and uremia.

Recent studies suggest that thyroid hormone replacement in CKD patients with subclinical hypothyroidism could slow down the rate of decline of renal function and thus may delay reaching end-stage renal disease [34, 35].

## CONCLUSION

In our study we have found high prevalence of subclinical and clinical hypothyroidism among hemodialysis patients, 26.6% of the study subjects had TSH levels above the reference range.

It was also shown that cold intolerance, constipation, dry skin and the presence of tingling sensation were much more common among patients with high TSH levels. Those subjects who also had serous effusions (pleural, pericardial or peritoneal) had a very high chance to have high TSH levels.

The diagnosis of hypothyroidism can be easily missed in the ESRD population, because the symptoms of CKD and hypothyroidism overlap. Timely diagnosis and treatment of hypothyroidism may prevent deterioration of patient condition and prolong survival.

Knowing the high prevalence, clinicians should pay attention on this factor and screen routinely for thyroid function disorders in the CKD population.

## LIMITATIONS

1. Selection bias – not all incident hemodialysis patients were included, and among the population not all patients who would need dialysis can afford it.
2. Small sample size.
3. Only a small geographical area was covered, thus not representative of the whole country.

## REFERENCES

- [1] Iglesias P, Diez JJ. Thyroid dysfunction and kidney disease. *European journal of endocrinology / European Federation of Endocrine Societies*. 2009;160(4):503-15. Epub 2008/12/20.
- [2] Amato AA, Santos GM, Neves Fde A. Thyroid hormone action in chronic kidney disease. *Current opinion in endocrinology, diabetes, and obesity*. 2008;15(5):459-65. Epub 2008/09/05.
- [3] Lim VS, Fang VS, Katz AI, Refetoff S. Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine. *The Journal of clinical investigation*. 1977;60(3):522-34. Epub 1977/09/01.
- [4] Hegedus L, Andersen JR, Poulsen LR, Perrild H, Holm B, Gundtoft E, et al. Thyroid gland volume and serum concentrations of thyroid hormones in chronic renal failure. *Nephron*. 1985;40(2):171-4. Epub 1985/01/01.
- [5] Kaptein EM, Quion-Verde H, Chooljian CJ, Tang WW, Friedman PE, Rodriguez HJ, et al. The thyroid in end-stage renal disease. *Medicine*. 1988;67(3):187-97. Epub 1988/05/01.
- [6] Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmark S, Witt MR, et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *Journal of internal medicine*. 2007;262(6):690-701. Epub 2007/10/03.
- [7] Lim VS. Thyroid function in patients with chronic renal failure. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2001;38(4 Suppl 1):S80-4. Epub 2001/09/29.
- [8] Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. *Clinical endocrinology*. 1977;7(6):481-93. Epub 1977/12/01.
- [9] Vanderpump M, Tunbridge W. *The epidemiology of thyroid disease*. In: Braverman LE, Utiger RD, editors. *The Thyroid*. 9th ed. Philadelphia: Lippincott-Raven Publishers; 1996. p. 474-82.
- [10] Usha Menon V, Sundaram KR, Unnikrishnan AG, Jayakumar RV, Nair V, Kumar H. High prevalence of undetected thyroid disorders in an iodine sufficient adult south Indian population. *Journal of the Indian Medical Association*. 2009;107(2):72-7. Epub 2009/07/10.
- [11] Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. *Kidney international*. 2005;67(3):1047-52. Epub 2005/02/09.
- [12] Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. *Clinical journal of the American Society of Nephrology : CJASN*. 2008;3(5):1296-300. Epub 2008/06/14.
- [13] Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Archives of internal medicine*. 2000;160(4):526-34. Epub 2000/03/01.
- [14] Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. *Endocrine reviews*. 1996;17(1):45-63. Epub 1996/02/01.
- [15] Czernichow P, Dazuet MC, Broyer M, Rappaport R. Abnormal TSH, PRL and GH response to TSH releasing factor in chronic renal failure. *The Journal of clinical endocrinology and metabolism*. 1976;43(3):630-7. Epub 1976/09/01.
- [16] Spector DA, Davis PJ, Helderman JH, Bell B, Utiger RD. Thyroid function and metabolic state in chronic renal failure. *Annals of internal medicine*. 1976;85(6):724-30. Epub 1976/12/01.
- [17] Spaulding SW, Gregerman RI. Free thyroxine in serum by equilibrium dialysis: effects of dilution, specific ions and inhibitors of binding. *The Journal of clinical endocrinology and metabolism*. 1972;34(6):974-82. Epub 1972/06/01.
- [18] Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. *Journal of the American Society of Nephrology : JASN*. 2005;16(9):2789-95. Epub 2005/07/22.
- [19] Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2004;19(5):1190-7. Epub 2004/03/03.
- [20] Ramirez G, O'Neill W, Jr., Jubiz W, Bloomer HA. Thyroid dysfunction in uremia: evidence for thyroid and hypophyseal abnormalities. *Annals of internal medicine*. 1976;84(6):672-6. Epub 1976/06/01.
- [21] Bando Y, Ushioji Y, Okafuji K, Toya D, Tanaka N, Miura S. Non-autoimmune primary hypothyroidism in diabetic and non-diabetic chronic renal dysfunction. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association*. 2002;110(8):408-15. Epub 2003/01/09.
- [22] Sato K, Okamura K, Yoshinari M, Kuroda T, Ikenoue H, Okazawa K, et al. Reversible primary hypothyroidism and elevated serum iodine level in patients with

- renal dysfunction. *Acta endocrinologica*. 1992;126(3):253-9. Epub 1992/03/01.
- [23] Brough R, Jones C. Iatrogenic iodine as a cause of hypothyroidism in infants with end-stage renal failure. *Pediatr Nephrol*. 2006;21(3):400-2. Epub 2005/12/31.
- [24] Sanai T, Inoue T, Okamura K, Sato K, Yamamoto K, Abe T, et al. Reversible primary hypothyroidism in Japanese patients undergoing maintenance hemodialysis. *Clinical nephrology*. 2008;69(2):107-13. Epub 2008/01/26.
- [25] Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Hypertension*. 2003;42(5):1050-65. Epub 2003/11/08.
- [26] Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. *Endocrine*. 2004;24(1):1-13. Epub 2004/07/14.
- [27] Bough EW, Crowley WF, Ridgway C, Walker H, Maloof F, Myers GS, et al. Myocardial function in hypothyroidism. Relation to disease severity and response to treatment. *Archives of internal medicine*. 1978;138(10):1476-80. Epub 1978/10/01.
- [28] Monzani F, Del Guerra P, Caraccio N, Pruneti CA, Pucci E, Luisi M, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment. *The Clinical investigator*. 1993;71(5):367-71. Epub 1993/05/01.
- [29] Constant EL, Adam S, Seron X, Bruyer R, Seghers A, Daumerie C. Anxiety and depression, attention, and executive functions in hypothyroidism. *Journal of the International Neuropsychological Society : JINS*. 2005;11(5):535-44. Epub 2005/10/11.
- [30] Monzani F, Caraccio N, Del Guerra P, Casolaro A, Ferrannini E. Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. *Clinical endocrinology*. 1999;51(2):237-42. Epub 1999/09/01.
- [31] Cukor D, Peterson RA, Cohen SD, Kimmel PL. Depression in end-stage renal disease hemodialysis patients. *Nature clinical practice Nephrology*. 2006;2(12):678-87. Epub 2006/11/25.
- [32] Antonijevic N, Nesovic M, Trbojevic B, Milosevic R. [Anemia in hypothyroidism]. *Medicinski preglod*. 1999;52(3-5):136-40. Epub 1999/10/13. Anemije u hipotireozu.
- [33] Fein HG, Rivlin RS. Anemia in thyroid diseases. *The Medical clinics of North America*. 1975;59(5):1133-45. Epub 1975/09/01.
- [34] Shin DH, Lee MJ, Kim SJ, et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. *J Clin Endocrinol Metab*. 2012; 97(8): 2732-40.
- [35] Shin DH, Lee MJ, Lee HS, et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. *Thyroid*. 2013; 23(6): 654-61.

**PARTICULARS OF CONTRIBUTORS:**

1. Clinical Fellow in Nephrology, Department of Renal Medicine and Transplantation, Barts Health NHS Trust, London, UK.

**NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:**

Dr. Klara Paudel,  
Clinical Fellow in Nephrology, Department of Internal Medicine, Renal Unit, Charak Memorial Medicare Hospital,  
Prithwi Chowk, Pokhara, Nepal.  
Phone: 00977-9856030567; 00977-9802823456, E-mail: klara.paudel@gmail.com

Date of Submission: **Oct 05, 2013**  
Date of Peer Review: **Dec 26, 2013**  
Date of Acceptance: **Feb 03, 2014**  
Date of Publishing: **Apr 15, 2014**

**FINANCIAL OR OTHER COMPETING INTERESTS:** None.